KRAS ^G12C Inhibition with Sotorasib in Advanced Solid Tumors

Abstract

Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the <i>KRAS</i> p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).

Keywords

MeSH Terms

Affiliated Institutions

• University of Ulsan KR
• Harvard University US
• Seoul National University KR
• Assistance Publique Hôpitaux de Marseille FR
• Pinnacle Clinical Research US
• HealthONE US
• Aix-Marseille Université FR
• University Health Network CA
• Indiana University – Purdue University Indianapolis US
• The Royal Melbourne Hospital AU
• Emory University US
• The University of Texas MD Anderson Cancer Center US
• New Generation University College ET
• Princess Margaret Cancer Centre CA
• Samsung Medical Center KR
• Weill Cornell Medicine US
• Roswell Park Comprehensive Cancer Center US
• UPMC Hillman Cancer Center US
• Peter MacCallum Cancer Centre AU
• City of Hope US
• Sarah Cannon Research Institute GB
• University of Pittsburgh Medical Center US
• Indiana University School of Medicine
• Inserm FR
• Duke Medical Center US
• The University of Adelaide AU
• University of Michigan US
• Centre de Recherche en Cancérologie de Marseille FR
• Ulsan College KR
• Dana-Farber Cancer Institute US
• Fox Chase Cancer Center US
• Amgen (United States) US
• Cancer Institute (WIA) IN
• Alvin J. Siteman Cancer Center
• National Cancer Center Hospital East JP
• University of Washington US
• Cornell University US
• University of California, San Francisco US
• Memorial Sloan Kettering Cancer Center US
• Sungkyunkwan University KR
• Asan Medical Center KR

Related Publications